We are live on !
Find out more
BVF Inc Portfolio holdings
AUM
$3.91B
Turnover
15.22%
1-Year Est. Return
304.52%
This Fund
S&P 500
This Quarter Est. Return
+12.99%
1 Year Est. Return
+304.52%
3 Year Est. Return
+591.72%
5 Year Est. Return
+1,391.93%
10 Year Est. Return
+28,184.7%
AUM
$644M
AUM Growth
+$56M
(+9.5%)
Cap. Flow
+$39.2M
Cap. Flow % of AUM
Cap. Flow %
6.09%
Top 10 Holdings %
Top 10 Hldgs %
67.17%
Holding
35
New
5
Increased
14
Reduced
6
Closed
1
Avg Time Held
1.5
years
Top 10 Avg Time Held
1.6
years
Top 20 Avg Time Held
1.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Array Biopharma Inc
ARRY
|
+$27M |
| 2 |
Forte Biosciences
FBRX
|
+$19.2M |
| 3 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
+$16M |
| 4 |
OMED
OncoMed Pharmaceuticals, Inc.
OMED
|
+$11M |
| 5 |
LOXO
Loxo Oncology, Inc
LOXO
|
+$7.94M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cytokinetics
CYTK
|
+$31.6M |
| 2 |
Blueprint Medicines
BPMC
|
+$21.7M |
| 3 |
IMDZ
Immune Design Corp.
IMDZ
|
+$8.39M |
| 4 |
CNCE
Concert Pharmaceuticals, Inc.
CNCE
|
+$7.07M |
| 5 |
Fate Therapeutics
FATE
|
+$5.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.22% |
| 2 | Miscellaneous | 0.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
DELISTED
Blueprint Medicines
BPMC
| $80.6M | 12.52% |
1,591,646
-510,634
| -24% | -$21.7M |
2015 Q2
8 quarters
|
|
2
DELISTED
ChemoCentryx, Inc.
CCXI
| $77.2M | 11.99% |
8,248,416
+257,844
| +3% | +$1.89M |
2013 Q2
16 quarters
|
|
|
3
DELISTED
Array Biopharma Inc
ARRY
| $50.7M | 7.88% |
6,059,625
+3,296,539
| +119% | +$27M |
2013 Q2
16 quarters
|
|
4
AnaptysBio
ANAB
$1.43B
| $39.7M | 6.17% |
1,659,200
-79,400
| -5% | -$2M |
2017 Q1
1 quarter
|
|
|
LOXO
5
DELISTED
Loxo Oncology, Inc
LOXO
| $37.2M | 5.77% |
463,386
+143,386
| +45% | +$7.94M |
2017 Q1
1 quarter
|
|
6
Crescent Biopharma
CBIO
$507M
| $33.1M | 5.15% |
29,702
+1,439
| +5% | +$1.19M |
2016 Q2
4 quarters
|
|
7
CytomX Therapeutics
CTMX
$432M
| $31.4M | 4.88% |
2,026,998
+222,323
| +12% | +$3.35M |
2015 Q4
6 quarters
|
|
|
CTIC
8
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $28.5M | 4.42% |
8,596,357
+4,116,666
| +92% | +$16M |
2015 Q3
7 quarters
|
|
|
FWP
9
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
| $28.2M | 4.38% |
198,265
| – | – |
2014 Q4
10 quarters
|
|
|
CNCE
10
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $25.9M | 4.02% |
1,856,895
-479,714
| -21% | -$7.07M |
2014 Q3
11 quarters
|
|
|
11
Cytokinetics
CYTK
$7.68B
| $24.1M | 3.74% |
1,990,321
-2,270,515
| -53% | -$31.6M |
2013 Q2
16 quarters
|
|
12
Palvella Therapeutics
PVLA
$2.54B
| $17.7M | 2.74% |
43,649
+19,686
| +82% | +$5.75M |
2016 Q2
4 quarters
|
|
|
ACHN
13
DELISTED
Achillion Pharmaceuticals
ACHN
| $16M | 2.49% |
3,490,077
+204,677
| +6% | +$823K |
2016 Q4
2 quarters
|
|
|
14
DELISTED
Forte Biosciences
FBRX
| $15.4M | 2.39% |
+3,411
| New | +$19.2M |
2017 Q2
0 quarters
|
|
15
BioLineRX
BLRX
$7.87M
| $14.9M | 2.31% |
29,167
| – | – |
2017 Q1
1 quarter
|
|
|
OMED
16
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $14.7M | 2.28% |
4,400,289
+2,639,800
| +150% | +$11M |
2013 Q3
15 quarters
|
|
|
INFI
17
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $12.4M | 1.92% |
7,866,108
| – | – |
2016 Q2
4 quarters
|
|
|
CASC
18
DELISTED
Cascadian Therapeutics, Inc.
CASC
| $11.6M | 1.81% |
3,133,224
| – | – |
2013 Q2
16 quarters
|
|
19
Xenon Pharmaceuticals
XENE
$3.92B
| $11.1M | 1.72% |
3,518,830
+569,036
| +19% | +$2.22M |
2014 Q4
10 quarters
|
|
20
DELISTED
Xoma
XOMA
| $10.5M | 1.63% |
1,502,800
| – | – |
2016 Q4
2 quarters
|
|
|
ARQL
21
DELISTED
Arqule Inc
ARQL
| $9.18M | 1.42% |
7,400,128
| – | – |
2013 Q2
16 quarters
|
|
|
FSTX
22
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
| $8.33M | 1.29% |
+153,846
| New | +$7.13M |
2017 Q2
0 quarters
|
|
|
RXDX
23
DELISTED
Ignyta, Inc.
RXDX
| $7.24M | 1.13% |
+700,000
| New | +$5.68M |
2017 Q2
0 quarters
|
|
24
DELISTED
Alpine Immune Sciences Inc
ALPN
| $6.37M | 0.99% |
661,202
+195,083
| +42% | +$1.87M |
2015 Q4
6 quarters
|
|
25
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| $5.86M | 0.91% |
7,917
| – | – |
2014 Q4
10 quarters
|
|
Similar funds
LFCM
AC
BVF Inc's Q2 2017 Portfolio in Review
As of Q2 2017, BVF Inc held 35 positions worth $644M, up 9.5% from $588M the previous quarter. Its ten largest holdings account for 67% of the portfolio.
BVF Inc deployed $39.2M of net new capital in Q2 2017, opening 5 new positions and adding to 14 existing holdings. Its largest new stake was Forte Biosciences: 3,411 shares worth $15.4M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Cytokinetics, an estimated $31.6M trimmed.
- BVF Inc's largest Q2 2017 buy was Forte Biosciences: 3,411 shares worth $15.4M.
- BVF Inc added most to Array Biopharma Inc in Q2 2017, an estimated $27M increase.
- BVF Inc's biggest Q2 2017 reduction was Cytokinetics, cutting an estimated $31.6M.
- BVF Inc fully exited Immune Design Corp. in Q2 2017, selling an estimated $8.39M.
- BVF Inc's ten largest holdings make up 67% of its $644M portfolio in Q2 2017.
- BVF Inc opened 5 new positions and closed 1 in Q2 2017.
- BVF Inc's portfolio value rose 9.5% quarter-over-quarter to $644M.
Based on BVF Inc's 13F filing for Q2 2017, filed 14 Aug 2017.